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Abstract: 
Hepatocellular carcinoma (HCC), in its very early stage, is heterogeneous both in terms of liver function (i.e., 
presence or absence of portal hypertension, model for end-stage liver disease score, Child-Pugh score 5 or 6, 
bilirubin level) and tumour characteristics (i.e., location, alpha-fetoprotein values, pathological features such as 
micro-vascular invasion, tumour grade and satellitosis). Existing evidence in comparing different curative options 
for patients with very early HCC is poor due to small sample sizes and lack of solid subgroup analyses. Large 
observational studies are available, with the potential to identify effective interventions in different subgroup of 
patients and to discover which treatments work ‘‘in a real world setting”. These studies suggest some important 
treatment selection strategies in very early HCC patients. According to extent of liver resection, and liver function, 
percutaneous ablation or liver resection are the recommended first line therapies in these patients. Laparoscopic 
surgery (resection or ablation) is the preferable strategy when the tumour is in the surface of the liver or close to 
extra-hepatic organs. Due to scarce donor resources and competition with patients at high transplant benefit (HCC 
patients unsuitable for non-transplant radical therapies and non-HCC patients with decompensated cirrhosis), 
transplantation is recommended only as second line therapy in patients with very early stage HCC in case of tumour 
recurrence or liver failure after ablation or liver resection. 
Keywords: Very early hepatocellular carcinoma; Evidence based treatment; personalized approach; Ablation; 
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INTRODUCTION: 
Liver cancer is the sixth most frequent cancer and the 
second most frequent cause of cancer related death 
worldwide. The incidence and mortality of 
hepatocellular carcinoma (HCC) in 2008 was 65,000 
and 60,240, respectively, in Europe compared with 
21,000 and 18,400, respectively, in the United States 
(US). Of particular concern is that both the incidence 
and mortality of HCC are increasing worldwide. In 
fact, it is estimated that by 2020 the number of cases 
in Asia and Europe and the US will reach 128,000, 
78,000 and 27,000, respectively. The prognostic 
classification of patients with HCC is complex, since 
any prognostic scheme has to account for both the 
background liver disease and the tumour itself. The 
management of HCC has significantly improved over 
the last decade related to a better knowledge of the 
natural history, improvements in staging systems and 
treatment algorithms, as well as emerging therapeutic 
options. One of the most reliable and widely adopted 
methods for staging HCC is the Barcelona Clinic 
Liver Cancer (BCLC) system, which stratifies 
patients according to the characteristics of the 
tumour, underlying liver disease and performance 
status. According to this system, the presence of an 
asymptomatic single nodule 62 cm, in the absence of 
vascular invasion or extra-hepatic disease, and in the 
presence of well-compensated cirrhosis is defined as 
very early stage HCC (BCLC stage 0). In recent 
years, largely due to improved surveillance programs 
in the cirrhotic population, more patients are being 
diagnosed with very early HCC. Although some of 
these patients may benefit from alcohol injection or 
transarterial chemoembolization (TACE), here we 
focus on the three treatment modalities considered to 
represent the best potential curative options for 
patients diagnosed with very early HCC [6]: liver 
resection (LR), liver transplantation (LT), and 
radiofrequency ablation (RFA). In general, patients 
with very early HCC who are treated with any of 
these strategies can have excellent recurrence-free 
and overall survival outcomes compared with patients 
who have more advanced tumors. In the last decade, 
the concept of ‘‘evidence based management” of 
patients with HCC has been introduced to define 
therapeutic strategies or algorithms derived from 
comparative studies evaluating treatment efficacy. 
Following the traditional pyramid of evidence based 
medicine (EBM), the best evidence is based on data 
obtained from randomized clinical trials (RCTs) or 
meta-analyses of RCTs. However, in the absence of 
RCTs, some treatment protocols have also been 
established based on the results of observational and 
cost-effectiveness studies.  
The concept of EBM continues to change over recent 
years, however, and the quality of data should be 
considered only in light of a more dynamic EBM 
paradigm. For example, the Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) working group has now 
replaced the traditional EBM pyramid and allows 
observational studies to be upgraded (or RCTs 
downgraded) along the evidence pyramid. Moreover, 
systematic reviews are omitted from the pyramid 
(i.e., in the revised pyramid, systematic reviews are a 
lens through which evidence is viewed/applied).  
Along with these changes, many experts worldwide 
now strongly support the use of observational studies 
and evidence derived from ‘‘big data” to develop and 
validate individual prognostic prediction and treat  
COMPARATIVE EFFICACY STUDIES OF 
PATIENTS WITH VERY EARLY HCC 
UNDERGOING CURATIVE THERAPIES: 
Clinical Trials: 
There are only a few randomised control trials that 
investigate curative options for patients with HCC, 
and all focus solely on the comparison of LR vs. 
RFA. Among the six RCTs (Table 1), three studies 
demonstrated a superiority of LR over RFA in terms 
of overall survival, while the other three reported 
comparable results with either therapy.  
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Of note, these trials were designed to detect relatively 
large differences in survival among patients with 
early HCC being treated by resection vs. ablation. In 
turn, these RCTs were likely underpowered and 
suffered from a small sample size to detect smaller 
differences in survival among the treatment groups. 
Moreover, enrolment criteria for these trials were 
heterogeneous in terms of tumour characteristics, 
liver function, and treatment procedures (i.e., RFA or 
microwave ablation were used in one trial, RFA plus 
TACE were used in another trial), thus making it 
difficult to interpret the data. The small sample size 
also made it difficult to examine subgroups to 
identify potential prognostic factors or identify 
whether one treatment might be superior to another 
(e.g., microwave vs. radiofrequency). Another 
important limit was that all of these RCT studies 
were solely conducted in Asia/China, thereby 
limiting the generalization of the results to the rest of 
the world. To mitigate some of the problems 
associated with these studies due to small sample 
size, meta-analyses of the RCT data have been 
performed. In one such meta-analysis, Qi et al. 
reported that LR was superior to RFA in terms of 
recurrence-free and overall survival. In contrast, LR 
had a higher incidence of post-operative 
complications compared with RFA. A separate study 
by Wang et al. similarly noted that LR was superior 
to RFA among patients with very early HCC, 
however LR was associated with a higher morbidity. 
Unfortunately, to date, there are no RCTs that 
directly compare LT with LR or RFA.  
Retrospective matched comparisons: 
In addition to the handful of prospective trials, 
numerous retrospective studies that compared LR vs. 
RFA or vs. LT for HCC have been published. 
Comparing the efficacy of different therapeutic 
modalities such as LT, LR, and RFA for HCC using 
retrospective data can be problematic. In particular, 
many of these studies suffer from selection bias and 
confounding by indication. Patients treated with RFA 
are usually older, have slightly worse liver function 
and most importantly, an increase in associated 
comorbidities (which contraindicate LR). In an 
attempt to simulate RCTs (i.e., comparative efficacy 
studies) and mitigate the inherent selection bias 
characteristic of retrospective studies, many 
investigators have adopted specific statistical 
techniques (i.e., case-matching, propensity score 
analysis, etc.) in an attempt to compare more 
homogeneous groups of patients. 
Several recent studies that specifically sought to 
compare LR and RFA for patients with very early 
stage HCC. Of note, three studies reported a similar 
overall survival and disease-free survival among 
patients treated with either LR or RFA; in contrast, 
one study reported better overall survival among 
patients undergoing RFA, especially for centrally 
located tumours. With regards to recurrence free 
survival (RFS), while most studies have noted a 
comparable RFS, two studies have reported a 
superior RFS for LR compared with RFA. The 
majority of studies demonstrated that LR had a 
significantly higher complication rate than RFA. 
Since much of the data on this topic have been 
published recently, no robust meta-analyses have yet 
been carried out. In general, however, data from 
retrospective studies have largely confirmed the 
results derived from the RCT subgroup meta-
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analyses that LR was associated with better disease-
free survival (DFS) than RFA for very early stage 
HCC patients, but LR has a higher postoperative 
morbidity.  
The BCLC algorithm does allow for an exception to 
this new treatment proposal in patients who are 
considered potential candidates for LT (based on 
patient’s age and presence of comorbidities). These 
patients, in fact, are recommended to undergo LR 
because, unlike other local therapy treatment options, 
the pathological examination of the resected tumour 
allows for the identification of patients at high risk of 
tumour recurrence (i.e., those who have the presence 
micro vascular invasion or additional nodules in the 
surgical specimen). For these patients, the BCLC 
proposes a policy of ‘‘ab initio” or preventive LT.  
The evidence to support this approach is, however, 
poor and based on a small single centre observational 
study without external validation. Moreover, it is well 
known that the rate of micro vascular invasion 
increases according to the tumour size, with an 
incidence of only 20–25% in very early HCC. Of 
note, since clinically relevant portal hypertension 
(PH) and high bilirubin levels are associated with 
high mortality and morbidity following LR, very 
early HCC patients with these clinical features of 
liver decompensating is considered non-respectable. 
In these patients, percutaneous ablation or primary 
LT are considered more appropriate first line 
therapies. 
Comparative effectiveness studies of patients with 
very early HCC undergoing curative therapies 
Large observational studies have the potential to 
identify effective interventions among different 
subgroup of patients and to delineate which treat 
approaches may work in a ‘‘real world” setting. In 
contrast, traditional randomized trials (or 
retrospective studies simulating a RCT) typically 
provide efficacy data for the ‘‘average” patient only. 
Recently, health institutions and laws have 
incorporated comparative effectiveness research as a 
scientific mechanism to help improve health care. It 
is likely that the amount of observational research 
will continue to increase, especially with studies that 
involve the statistical analysis of large administrative 
databases and electronic medical records (i.e., big 
data). HCC, in its very early stage, is heterogeneous 
both in terms of liver function (i.e., presence or 
absence of PH, model for end-stage liver disease 
score, Child-Pugh score 5 or 6, bilirubin level) and 
tumour characteristics (i.e., location, alpha-
fetoprotein values, pathological features such as 
micro vascular invasion, tumour grade and 
satellitosis). 
Tumour location, need for extensive or complex liver 
resection, local donor resources and waiting list 
pressure are some examples of the important 
variables that need to be considered among patients 
with HCC. In turn, such variables can confound and 
complicate the clinical picture, contributing to why 
trials in this setting are challenging and likely will 
never totally inform treatment decisions for 
individual patients. The nuanced and individual 
context of each case also explains why strict 
treatment algorithms are often not followed in 
clinical practice in a large proportion of patients 
worldwide. For these reasons, the evidence for the 
personalized approach derives not only from RCTs 
but also from large cohort studies that may reflect the 
actual clinical setting and allow for generalization of 
results due to the high numbers of patients included 
in most studies. 
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Figure 1 
Well-designed observational studies can offer 
compelling evidence to define the main prognostic 
factors within each treatment group (i.e., tumour size 
or location for the ablation group, liver dysfunction 
for the resection group). The results of prognostic 
studies, therefore, may be used for a qualitative 
assessment of treatment effectiveness in different 
subgroups of patients with very early HCC. Large 
observational studies can sometimes be transformed 
into quantitative comparative analyses by using 
specific statistical simulation/modelling strategies. 
The robustness of these studies typically depends on 
the strength of the survival model used to predict 
individual survival in different treatment groups. The 
higher the prognostic power of multivariate survival 
models, the higher the intrinsic statistical evidence of 
the simulation results. Simulation studies may also be 
based on solid data from the literature, such as meta-
analyses. Furthermore, simulation studies may 
include other outcome measures such as quality of 
life and costs. 
Liver transplantation for very early HCC: 
The first decision rule in the BCLC algorithm is 
whether the patient is a potential candidate for LT 
(Fig. 1). As noted above, LT is generally considered 
the best treatment modality for HCC, as it extirpates 
both the tumour within the liver as well as the 
remaining oncogenic cirrhotic tissue caused by the 
underlying pathology. The disparity between scarce 
organ donors and the increased number of patients on 
the waiting list is the main limitation of LT. This 
crucial limit of LT requires the adoption of specific 
allocation principles. There are at least two possible 
bases for organ allocation: medical urgency and 
utility. A utility-based system would assign priority 
in accordance with expected post-transplant 
outcomes. Based on utility, therefore, patients with 
very early HCC should receive the highest priority 
for LT because these patients have the lowest risk of 
post-transplant HCC recurrence. Conversely, under a 
medical urgency-based allocation system, patients 
with worse waiting list outcomes are given higher 
priority or transplantation. This is what actually 
happens in many countries worldwide for non HCC 
patients prioritized according to the model for end-
stage liver disease (MELD) score. 
According to this principle, very early stage HCC 
represents the category of HCC patients with the 
lowest survival benefit from LT. Based on this 
consideration; LT remains a second line treatment for 
patients with very early HCC. The main benefit of LT 
is the treatment of recurrence after LR or RFA. 
Several authors have recently used the results of 
multivariate survival analyses to compare the 
outcome of HCC patients with and without LT. The 
survival benefit of LT in HCC patients was strongly 
influenced by liver function and availability of 
alternative therapies. Patients with the highest benefit 
from LT were those patients without the option of 
receiving a radical alternative therapy (for example 
BCLC B patients) or those with decompensated 
cirrhosis (Child-Pugh class C). Some authors have 
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also specifically demonstrated that, from a transplant 
benefit point of view, LT should be contraindicated 
in patients with respectable HCC, particularly when 
the tumour is single and the patient has a low MELD 
score. 
The evidence suggests three important 
considerations:  
1) Comparative ‘‘efficacy” studies have shown that 
LR offers better DFS than RFA at the price of 
higher postoperative morbidity. This finding is 
an average result obtained in underpowered 
comparative studies. In larger comparative 
‘‘effectiveness” studies the difference in DFS 
translates into a significantly higher long-term 
survival after LR compared with RFA among 
well-selected patients with very early HCC. 
2) Laparoscopic ablation is an important therapeutic 
procedure available in real life clinical practice 
ignored by current guidelines. The minimal 
invasive approach has the potential to overcome 
some limits of percutaneous ablation particularly 
in patients with very early HCC in ‘‘high risk 
locations” (i.e., surface or partially exophytic 
lesions closed to abdominal organs).  
3) Based on the transplant benefit principle, LT has 
the lowest survival benefit among patient with 
very early HCC compared with patients who 
have HCC that is more advanced according to 
the BCLC stages. 
 
CONCLUSION: 
Based on these considerations, LR is probably 
justified as first line therapy in very early HCC only 
when the risk of postoperative LD is comparable to 
that of non-resection approaches. According to recent 
evidence, an optimal postoperative result can be 
obtained among very early HCC patients using a 
minor LR in the absence of clinically relevant PH and 
with a MELD score 69. Among patients with PH, 
optimal results are better achieved with a 
laparoscopic minor LR. 
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